Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    Medical Dialogues Bureau
    Medical Dialogues Bureau

      Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers.  Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in. Check out more about our bureau/team here

      • Home
      • Medical Dialogues...

      Articles By : Medical Dialogues Bureau

      Novartis to buy France

      Novartis to buy France's CellforCure to boost cell, gene therapy

      Medical Dialogues Bureau24 Dec 2018 9:00 AM IST
      Novartis, which already has an agreement with CellforCure to help make Kymriah, said it aims to add CellforCure's facilities to a similar factory in...
      Aurobindo Pharma gets USFDA nod for Potassium Chloride extended-release tablets

      Aurobindo Pharma gets USFDA nod for Potassium Chloride extended-release tablets

      Medical Dialogues Bureau23 Dec 2018 9:59 AM IST
      "The company has received final approval from the US Food and Drug Administration (USFDA) for Potassium Chloride extended-release tablets in the...
      USFDA panel backs prescribing NALOXONE along with painkillers

      USFDA panel backs prescribing NALOXONE along with painkillers

      Medical Dialogues Bureau23 Dec 2018 9:15 AM IST
      The prescription of naloxone could facilitate a healthy dialogue between patients and the healthcare provider, Maryann Amirshahi, a panel member who...
      Pharma industry returns on R&D investment hit 9-year low

      Pharma industry returns on R&D investment hit 9-year low

      Medical Dialogues Bureau23 Dec 2018 9:00 AM IST
      An annual survey of the economics of pharma research and development (R&D) by the consultancy found that despite a steady flow of new medicines...
      New Rhein Healthcare announces first closing of its inaugural fund

      New Rhein Healthcare announces first closing of its inaugural fund

      Medical Dialogues Bureau22 Dec 2018 9:00 AM IST
      New Rhein fund closed on $47.7 million of commitments with an additional $15 million commitment to be automatically released upon achieving a targeted...
      AstraZeneca gets USFDA nod for LYNPARZA as maintenance treatment

      AstraZeneca gets USFDA nod for LYNPARZA as maintenance treatment

      Medical Dialogues Bureau21 Dec 2018 9:33 AM IST
      The approval was based on positive results from a late-stage study in which the drug, Lynparza, reduced the risk of disease progression or death by 70...
      Indivior to launch Sublocade; maintains revenue forecast

      Indivior to launch Sublocade; maintains revenue forecast

      Medical Dialogues Bureau21 Dec 2018 9:00 AM IST
      Indivior also said revenue from its new opioid addiction treatment, Sublocade, would exceed the top end of its previous 2018 forecast range of $8...
      Asbestos scare: CDSCO draws samples of J&J baby powder from HP plant

      Asbestos scare: CDSCO draws samples of J&J baby powder from HP plant

      Medical Dialogues Bureau20 Dec 2018 5:12 PM IST
      The CDSCO, under the Union Health Ministry, said over the next four to five days, drug inspectors will search manufacturing plants and wholesalers of...
      MTaI welcomes government decision to create National Medical Devices Promotion Council

      MTaI welcomes government decision to create National Medical Devices Promotion Council

      Medical Dialogues Bureau20 Dec 2018 9:30 AM IST
      Pavan Choudary, Chairman, Medical Technology Association of India (MTaI) said, "Within the overall health ecosystem, medical devices has remained a...
      China first to approve AstraZeneca, FibroGen Roxadustat

      China first to approve AstraZeneca, FibroGen Roxadustat

      Medical Dialogues Bureau20 Dec 2018 9:16 AM IST
      Roxadustat is the first of a new kind of oral anaemia treatment called a hypoxia-inducible factor prolyl hydroxylase inhibitor that boosts production...
      Biocon,Mylan get EU approval for biosimilar of cancer drug

      Biocon,Mylan get EU approval for biosimilar of cancer drug

      Medical Dialogues Bureau20 Dec 2018 9:00 AM IST
      "Ogivri, a biosimilar Trastuzumab jointly developed by Biocon and Mylan, has been approved in the EU. The European Commission has granted marketing...
      Lupin gets USFDA tentative approval for generic tablets to treat Erectile Dysfunction

      Lupin gets USFDA tentative approval for generic tablets to treat Erectile Dysfunction

      Medical Dialogues Bureau18 Dec 2018 5:36 PM IST
      New Delhi: Drug maker Lupin recently said it has received tentative approval from the US health regulator for Tadalafil tablets, used to treat...
      PrevNext

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok